Approximately 85% of children diagnosed with cancer will be cured of their primary cancer, but epidemiologic and clinical studies have characterized a significant burden of morbidity, as well as excess early mortality, in survivors.
This burden has largely been attributed to toxic treatment exposures during childhood cancer treatment. Excess cardiovascular-related disease is a leading cause of morbidity and mortality in survivors of childhood cancer, which is associated with exposure to cardiotoxic therapy, such as anthracyclines and therapeutic radiation to the chest